-
Our Vision
to relieve patient suffering and enhance lives
Using our novel R&D platform for the advancement of life-changing medicines, we focus on neurological and endocrine based diseases and disorders.
Learn More -
Tardive Dyskinesia
is a potentially debilitating movement disorder.
We have a novel product approved for the treatment of adults with involuntary movements caused by exposure to dopamine receptor blocking agents.
Learn More -
Endometriosis and Uterine Fibroids
Not all patients suffer the same way.
We are investigating a first-in-class, oral treatment option that addresses the chronic, intermittent, predictable and unpredictable symptoms common to Endometriosis and Uterine Fibroids.
Learn More
-
Tourette Syndrome
can mean life interrupted.
We are investigating a once-daily treatment for tics associated with Tourette syndrome.
Learn More -
Congenital Adrenal Hyperplasia
requires life long care.
We are investigating a non-steroidal therapy for Classical CAH to treat the effects of life-long elevated androgens and the use of high-dose corticosteroids both of which can lead to the virilization of females, metabolic syndrome, bone loss, growth impairment, and Cushing's syndrome.
Learn More
You are now leaving the Neurocrine website.
Neurocrine is not responsible for the content of linked third party websites. Please be aware that the privacy policies and terms of use on these sites are different from Neurocrine policies.